Syros Pharmaceuticals (SYRS) Stock Forecast, Price Target & Predictions
SYRS Stock Forecast
Syros Pharmaceuticals stock forecast is as follows: an average price target of $16.67 (represents a 6311.54% upside from SYRS’s last price of $0.26) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
SYRS Price Target
SYRS Analyst Ratings
Buy
Syros Pharmaceuticals Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Oct 23, 2024 | Edward Tenthoff | Piper Sandler | $5.00 | $2.47 | 102.43% | 1823.08% |
Jun 26, 2024 | Edward Tenthoff | Piper Sandler | $13.00 | $5.70 | 128.07% | 4900.00% |
Jun 26, 2024 | Andrew Fein | H.C. Wainwright | $15.00 | $5.70 | 163.16% | 5669.23% |
Aug 09, 2022 | Mark Breidenbach | Oppenheimer | $30.00 | $9.27 | 223.52% | 11438.46% |
10
Syros Pharmaceuticals Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 1 | 1 | 3 |
Avg Price Target | $5.00 | $5.00 | $11.00 |
Last Closing Price | $0.26 | $0.26 | $0.26 |
Upside/Downside | 1823.08% | 1823.08% | 4130.77% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Nov 13, 2024 | JMP Securities | Market Outperform | Perform | Downgrade |
Oct 23, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Jun 26, 2024 | Cowen & Co. | Buy | Buy | Hold |
Jun 26, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Jun 26, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Jun 25, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
Jan 05, 2023 | Piper Sandler | Overweight | Overweight | Hold |
Sep 19, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Aug 09, 2022 | Oppenheimer | Outperform | Outperform | Hold |
May 17, 2022 | Alliance Global Partners | Buy | Buy | Hold |
10
Syros Pharmaceuticals Financial Forecast
Syros Pharmaceuticals Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | $3.76M | $2.83M | $2.95M | $-5.47M | $3.89M | $6.28M | $5.47M | $7.80M | $5.70M | $5.16M | $4.83M | $5.70M | $3.83M | $3.19M | $2.38M | $508.00K | $558.00K | $462.00K | $454.00K | $370.00K | $1.10M |
Avg Forecast | - | - | - | - | $450.00K | $360.00K | $460.00K | $720.00K | $2.00M | $3.94M | $3.50M | $3.30M | $3.85M | $5.18M | $4.74M | $4.92M | $4.81M | $4.49M | $4.13M | $2.67M | $2.64M | $2.54M | $1.90M | $1.87M | $691.29K | $441.17K | $430.29K | $430.29K | $300.63K | $1.33M |
High Forecast | - | - | - | - | $450.00K | $360.00K | $460.00K | $720.00K | $2.92M | $3.94M | $3.50M | $3.30M | $3.85M | $5.18M | $4.74M | $4.92M | $4.81M | $4.49M | $4.13M | $2.67M | $2.64M | $2.54M | $1.90M | $1.87M | $691.29K | $441.17K | $430.29K | $430.29K | $360.75K | $1.59M |
Low Forecast | - | - | - | - | $450.00K | $360.00K | $460.00K | $720.00K | $1.08M | $3.94M | $3.50M | $3.30M | $3.85M | $5.18M | $4.74M | $4.92M | $4.81M | $4.49M | $4.13M | $2.67M | $2.64M | $2.54M | $1.90M | $1.87M | $691.29K | $441.17K | $430.29K | $430.29K | $240.50K | $1.06M |
# Analysts | - | - | - | - | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 11 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 16 |
Surprise % | - | - | - | - | - | - | - | - | - | 0.95% | 0.81% | 0.89% | -1.42% | 0.75% | 1.32% | 1.11% | 1.62% | 1.27% | 1.25% | 1.81% | 2.16% | 1.50% | 1.68% | 1.27% | 0.73% | 1.26% | 1.07% | 1.06% | 1.23% | 0.83% |
Forecast
Syros Pharmaceuticals EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 11 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 16 |
EBITDA | - | - | - | - | - | - | - | - | - | $-34.64M | $-34.00M | $-30.80M | $-33.63M | $-38.34M | $-32.93M | $-25.87M | $-22.05M | $-24.28M | $-20.77M | $-12.53M | $-29.36M | $-18.72M | $-16.44M | $-16.48M | $-18.83M | $-19.15M | $-18.81M | $-15.93M | $-14.07M | $-11.15M |
Avg Forecast | - | - | - | - | $-450.00K | $-360.00K | $-460.00K | $-720.00K | $-2.00M | $-3.94M | $-3.50M | $-3.30M | $-3.85M | $-5.18M | $-4.74M | $-4.92M | $-4.81M | $-4.49M | $-4.13M | $-16.92M | $-2.64M | $-2.54M | $-1.90M | $-18.02M | $-691.29K | $-441.17K | $-430.29K | $-18.16M | $-10.83M | $-13.04M |
High Forecast | - | - | - | - | $-450.00K | $-360.00K | $-460.00K | $-720.00K | $-1.08M | $-3.94M | $-3.50M | $-3.30M | $-3.85M | $-5.18M | $-4.74M | $-4.92M | $-4.81M | $-4.49M | $-4.13M | $-13.53M | $-2.64M | $-2.54M | $-1.90M | $-14.41M | $-691.29K | $-441.17K | $-430.29K | $-14.53M | $-8.66M | $-10.43M |
Low Forecast | - | - | - | - | $-450.00K | $-360.00K | $-460.00K | $-720.00K | $-2.92M | $-3.94M | $-3.50M | $-3.30M | $-3.85M | $-5.18M | $-4.74M | $-4.92M | $-4.81M | $-4.49M | $-4.13M | $-20.30M | $-2.64M | $-2.54M | $-1.90M | $-21.62M | $-691.29K | $-441.17K | $-430.29K | $-21.80M | $-12.99M | $-15.65M |
Surprise % | - | - | - | - | - | - | - | - | - | 8.79% | 9.71% | 9.33% | 8.74% | 7.40% | 6.95% | 5.25% | 4.59% | 5.41% | 5.02% | 0.74% | 11.13% | 7.36% | 8.64% | 0.91% | 27.24% | 43.41% | 43.71% | 0.88% | 1.30% | 0.86% |
Forecast
Syros Pharmaceuticals Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 11 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 16 |
Net Income | - | - | - | - | - | - | - | - | - | $-40.14M | - | $-14.92M | $27.57M | $-21.05M | $-35.19M | $-23.64M | $-24.80M | $-26.03M | $-22.49M | $-14.23M | $-30.13M | $-19.49M | $-17.20M | $-17.23M | $-19.73M | $-19.79M | $-19.45M | $-16.46M | $-14.46M | $-11.52M |
Avg Forecast | $-16.69M | $-17.28M | $-18.85M | $-21.21M | $-27.19M | $-26.56M | $-30.14M | $-33.27M | $-44.92M | $-44.77M | $-44.30M | $-41.17M | $-48.11M | $-152.52M | $-160.22M | $-184.57M | $-181.76M | $-171.80M | $-145.30M | $-19.21M | $-195.86M | $-151.19M | $-158.55M | $-18.83M | $-180.64M | $-181.29M | $-161.00M | $-18.77M | $-11.13M | $-13.47M |
High Forecast | $-16.69M | $-17.28M | $-18.85M | $-21.21M | $-25.05M | $-26.56M | $-30.14M | $-33.27M | $-39.08M | $-44.77M | $-44.30M | $-41.17M | $-48.11M | $-152.52M | $-160.22M | $-184.57M | $-181.76M | $-171.80M | $-145.30M | $-15.37M | $-195.86M | $-151.19M | $-158.55M | $-15.06M | $-180.64M | $-181.29M | $-161.00M | $-15.02M | $-8.90M | $-10.77M |
Low Forecast | $-16.69M | $-17.28M | $-18.85M | $-21.21M | $-28.98M | $-26.56M | $-30.14M | $-33.27M | $-50.40M | $-44.77M | $-44.30M | $-41.17M | $-48.11M | $-152.52M | $-160.22M | $-184.57M | $-181.76M | $-171.80M | $-145.30M | $-23.05M | $-195.86M | $-151.19M | $-158.55M | $-22.59M | $-180.64M | $-181.29M | $-161.00M | $-22.53M | $-13.35M | $-16.16M |
Surprise % | - | - | - | - | - | - | - | - | - | 0.90% | - | 0.36% | -0.57% | 0.14% | 0.22% | 0.13% | 0.14% | 0.15% | 0.15% | 0.74% | 0.15% | 0.13% | 0.11% | 0.91% | 0.11% | 0.11% | 0.12% | 0.88% | 1.30% | 0.86% |
Forecast
Syros Pharmaceuticals SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 11 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 16 |
SG&A | - | - | - | - | - | - | - | - | - | $7.76M | $7.22M | $7.41M | $7.33M | $8.08M | $6.95M | $6.95M | $6.43M | $5.35M | $5.52M | $5.74M | $5.89M | $5.15M | $5.13M | $5.15M | $6.40M | $5.02M | $5.20M | $4.87M | $4.08M | $3.09M |
Avg Forecast | - | - | - | - | $1.62M | $1.30M | $1.66M | $2.60M | $7.22M | $14.22M | $12.63M | $11.92M | $13.90M | $18.70M | $17.11M | $17.77M | $17.35M | $16.20M | $14.92M | $9.64M | $9.52M | $9.18M | $6.87M | $6.76M | $2.49M | $1.59M | $1.55M | $1.55M | $1.08M | $4.78M |
High Forecast | - | - | - | - | $1.62M | $1.30M | $1.66M | $2.60M | $10.53M | $14.22M | $12.63M | $11.92M | $13.90M | $18.70M | $17.11M | $17.77M | $17.35M | $16.20M | $14.92M | $9.64M | $9.52M | $9.18M | $6.87M | $6.76M | $2.49M | $1.59M | $1.55M | $1.55M | $1.30M | $5.74M |
Low Forecast | - | - | - | - | $1.62M | $1.30M | $1.66M | $2.60M | $3.91M | $14.22M | $12.63M | $11.92M | $13.90M | $18.70M | $17.11M | $17.77M | $17.35M | $16.20M | $14.92M | $9.64M | $9.52M | $9.18M | $6.87M | $6.76M | $2.49M | $1.59M | $1.55M | $1.55M | $867.99K | $3.83M |
Surprise % | - | - | - | - | - | - | - | - | - | 0.55% | 0.57% | 0.62% | 0.53% | 0.43% | 0.41% | 0.39% | 0.37% | 0.33% | 0.37% | 0.60% | 0.62% | 0.56% | 0.75% | 0.76% | 2.57% | 3.15% | 3.35% | 3.13% | 3.76% | 0.64% |
Forecast
Syros Pharmaceuticals EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 11 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 16 |
EPS | - | - | - | - | - | - | - | - | - | $-1.43 | $-1.30 | $-0.54 | $5.99 | $-2.24 | $-5.51 | $-3.75 | $-3.94 | $-4.14 | $-3.58 | $-2.32 | $-4.91 | $-4.26 | $-3.76 | $-3.92 | $-4.49 | $-4.66 | $-4.67 | $-4.87 | $-4.77 | $-4.92 |
Avg Forecast | $-0.42 | $-0.44 | $-0.48 | $-0.54 | $-0.69 | $-0.68 | $-0.77 | $-0.85 | $-1.14 | $-1.14 | $-1.13 | $-1.05 | $-1.23 | $-3.88 | $-4.08 | $-4.70 | $-4.63 | $-4.38 | $-3.70 | $-4.64 | $-4.99 | $-3.85 | $-4.04 | $-4.21 | $-4.60 | $-4.62 | $-4.10 | $-5.60 | $-0.30 | $-0.69 |
High Forecast | $-0.42 | $-0.44 | $-0.48 | $-0.54 | $-0.64 | $-0.68 | $-0.77 | $-0.85 | $-1.00 | $-1.14 | $-1.13 | $-1.05 | $-1.23 | $-3.88 | $-4.08 | $-4.70 | $-4.63 | $-4.38 | $-3.70 | $-4.64 | $-4.99 | $-3.85 | $-4.04 | $-4.21 | $-4.60 | $-4.62 | $-4.10 | $-5.60 | $-0.24 | $-0.55 |
Low Forecast | $-0.42 | $-0.44 | $-0.48 | $-0.54 | $-0.74 | $-0.68 | $-0.77 | $-0.85 | $-1.28 | $-1.14 | $-1.13 | $-1.05 | $-1.23 | $-3.88 | $-4.08 | $-4.70 | $-4.63 | $-4.38 | $-3.70 | $-4.64 | $-4.99 | $-3.85 | $-4.04 | $-4.21 | $-4.60 | $-4.62 | $-4.10 | $-5.60 | $-0.36 | $-0.83 |
Surprise % | - | - | - | - | - | - | - | - | - | 1.25% | 1.15% | 0.52% | -4.89% | 0.58% | 1.35% | 0.80% | 0.85% | 0.95% | 0.97% | 0.50% | 0.98% | 1.11% | 0.93% | 0.93% | 0.98% | 1.01% | 1.14% | 0.87% | 15.89% | 7.13% |
Forecast
Syros Pharmaceuticals Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
SYRS | Syros Pharmaceuticals | $0.26 | $16.67 | 6311.54% | Buy |
PASG | Passage Bio | $0.54 | $6.00 | 1011.11% | Buy |
SPRO | Spero Therapeutics | $1.19 | $10.00 | 740.34% | Buy |
CHRS | Coherus BioSciences | $1.10 | $9.00 | 718.18% | Hold |
BDTX | Black Diamond Therapeutics | $2.43 | $14.75 | 507.00% | Buy |
RGNX | REGENXBIO | $9.18 | $32.00 | 248.58% | Buy |
LRMR | Larimar Therapeutics | $6.13 | $20.33 | 231.65% | Buy |
FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
STOK | Stoke Therapeutics | $11.27 | $30.60 | 171.52% | Buy |
KZR | Kezar Life Sciences | $7.62 | $17.50 | 129.66% | Buy |
SNDX | Syndax Pharmaceuticals | $15.60 | $34.30 | 119.87% | Buy |
KROS | Keros Therapeutics | $53.84 | $102.60 | 90.56% | Buy |
KRON | Kronos Bio | $0.87 | $1.63 | 87.36% | Buy |
XNCR | Xencor | $24.10 | $42.60 | 76.76% | Buy |
BOLT | Bolt Biotherapeutics | $0.57 | $1.00 | 75.44% | Hold |
IDYA | IDEAYA Biosciences | $26.60 | $46.58 | 75.11% | Buy |
CRNX | Crinetics Pharmaceuticals | $57.03 | $70.14 | 22.99% | Buy |
GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |